The first important breakthrough was the development of imatinib, a BCR-ABL tyrosine kinase inhibitor (TKI), for chronic myeloid leukemia (CML) patients harboring the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.